Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Meta-analyses of Fructose and Cardiometabolic Risk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01363791
Recruitment Status : Unknown
Verified May 2015 by John Sievenpiper, University of Toronto.
Recruitment status was:  Active, not recruiting
First Posted : June 2, 2011
Last Update Posted : May 27, 2015
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
Canada Research Chairs Endowment of the Federal Government of Canada
Calorie Control Council
Information provided by (Responsible Party):
John Sievenpiper, University of Toronto

Tracking Information
First Submitted Date May 25, 2011
First Posted Date June 2, 2011
Last Update Posted Date May 27, 2015
Study Start Date May 2009
Actual Primary Completion Date March 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 23, 2012)
  • Lipid Analysis [ Time Frame: June 2012 ]
    Analyses:
    1. Fasting lipids (triglycerides, HDL-cholesterol [C], LDL-C, apo-B, total-C:HDL-C ratio, apo-B:apo-A1 ratio, non-HDL-C)
    2. Postprandial lipids (peak, mean, and area under the curve [AUC] triglycerides)
  • Body Weight Analysis [ Time Frame: November 2011 ]
    Analyses: 1. Body weight
  • Glycemic Control Analysis [ Time Frame: June 2012 ]
    Analyses:
    1. Glycated blood proteins (HbA1c, fructosamine, glycated albumin), glucose, and insulin in people with diabetes
    2. Glycated blood proteins (HbA1c, fructosamine, glycated albumin), glucose, and insulin in people without diabetes
    3. Insulin sensitivity (Euglycemic-hyperinsulinemic clamp, frequent sampling intravenous glucose tolerance test [FSIGT], Homeostasis model assessment of insulin resistance [HOMA-IR], oral glucose tolerance test insulin sensitivity index [OGTT-ISI])
  • Blood Pressure (BP) Analysis [ Time Frame: January 2012 ]
    Analyses: 1. Systolic BP, diastolic BP, and mean arterial pressure (MAP)
  • Uric Acid Analysis [ Time Frame: February 2012 ]
    Analyses: 1. uric acid
  • "Catalytic" Fructose Across Cardiometabolic Endpoints Analysis [ Time Frame: January 2012 ]
    Analyses: 1. Lipids, glycemic control, body weight, blood pressure, and uric acid
  • Non-Alcoholic Fatty Liver (NAFL) Analysis [ Time Frame: June 2012 ]
    Analyses: 1. Imaging and spectroscopy endpoints of liver fat (Liver ultrasound [US], computed tomography [CT], magnetic resonance imaging [MRI], or magnetic resonance spectroscopy [MRS]) and biomarkers of hepatocellular injury (transaminases [ALT, AST, GGT])
Original Primary Outcome Measures
 (submitted: June 1, 2011)
  • Lipid Analysis [ Time Frame: March 2012 ]
  • Body Weight Analysis [ Time Frame: March 2012 ]
  • Glycemic Control Analysis [ Time Frame: March 2012 ]
  • Blood Pressure Analysis [ Time Frame: March 2012 ]
  • Uric Acid Analysis [ Time Frame: March 2012 ]
  • Catalytic Analysis [ Time Frame: March 2012 ]
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Meta-analyses of Fructose and Cardiometabolic Risk
Official Title Effect of Fructose on Metabolic Control in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development
Brief Summary Diabetes and heart associations continue to discourage high intakes of dietary fructose, a constituent part of the sucrose molecule that is found in fruits and vegetables as a natural sugar and in some processed foods and beverages as an added sweetener. The concern relates to its ability to increase certain blood fats and cholesterol, which increase the risk of cardiovascular disease. The evidence for an adverse effect of fructose on these risk factors, however, is inconclusive. To improve the evidence on which nutrition recommendations for fructose are based, the investigators therefore propose to study the effect of fructose on blood fats, cholesterol, sugars, blood pressure, and body weight, by undertaking a systematic synthesis of the data taken from all available clinical studies in humans. This technique has the strength of allowing all of the available data to be pooled together and differences to be explored in groups of different study participants (healthy humans of different sex, weight, and age and in those with diseases which predispose to disturbances in metabolism, such as diabetes) with dietary fructose in different forms, doses, and with differing durations of exposure. The findings generated by this proposed knowledge synthesis will help improve the health of consumers through informing recommendations for the general public, as well as those at risk of diabetes and cardiovascular disease.
Detailed Description

Background: Fructose has been implicated in chronic disease guidelines. The American Heart Association (AHA) and American (ADA), Canadian (CDA), and European (EASD) Diabetes Associations discourage dietary fructose at high intakes (>15-20% energy), citing its ability to aggravate blood lipids. The American Heart Association (AHA) and the World Health Organization (WHO) recommend reduced consumption (<5-7% and <10% energy, respectively) of added sugars, especially as high fructose corn syrup in sugar sweetened beverages, to decrease the risk of weight gain. These concerns, however, are based on inconsistent intervention data in humans. There is also paradoxical evidence that small, catalytic doses of fructose at a level obtainable from fruit (<10-g/meal) may improve glycemic control in humans.

Objective: To improve evidence-based guidance for fructose recommendations, the investigators propose conducting a series of 7 systematic reviews and meta-analyses of controlled feeding trials to assess the effect of oral fructose on cardiometabolic risk in humans. The first 6 systematic reviews and meta-analyses will each be conducted on a different area of cardiometabolic risk: (1) lipids, (2) glycemic control, (3) body weight, (4) uric acid, (5) blood pressure, and (6) non-alcoholic fatty liver (NAFL). The seventh meta-analysis will investigate the effect of small, "catalytic" doses of fructose at a level obtainable from fruit (<10-g/meal) on all areas of cardiometabolic risk.

Design: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.

Data sources. MEDLINE, EMBASE, CINAHL and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms, supplemented by manual, hand searches of bibliographies.

Study selection: We will include controlled feeding trials investigating the effect of fructose in isocaloric exchange for other carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials) on cardiometabolic risk factors in humans. Studies that are <7-days diet duration, lack a control, or do not provide viable endpoint data will be excluded. To isolate the effects of fructose, we will also exclude trials in which fructose was administered exclusively as sucrose (bound fructose) or high-fructose corn syrup (42% to 55% of free fructose), except where these sweeteners were the comparator.

Data extraction. Two investigators will independently extract information about study design, sample size, subject characteristics, fructose form, dose, reference-carbohydrate, follow-up, and background diet profile. Mean±SEM values will be extracted for all outcomes. Standard computations and imputations will be used to derive missing variance data. Investigators will assess the quality/validity of each study using the Heyland Methodological Quality Score (MQS).

Outcomes: The first 6 of 7 proposed analyses will each assess a set of outcomes related to a different area of cardiometabolic risk: (1) lipids (fasting lipids [triglycerides, HDL-cholesterol [C], LDL-C, apo-B, total-C:HDL-C ratio, apo-B:apo-A1 ratio, non-HDL-C] and postprandial lipids(non-fasting peak, mean, and area under the curve [AUC] triglycerides), (2) glycemic control (fasting glucose and insulin, glycated blood proteins) and insulin sensitivity (Euglycemic-hyperinsulinemic clamp, frequent sampling intravenous glucose tolerance test [FSIGT], Homeostasis model assessment of insulin resistance [HOMA-IR], oral glucose tolerance test insulin sensitivity index [OGTT-ISI]), (3) body weight, (4) uric acid, (5) blood pressure (systolic BP, diastolic BP, mean arterial pressure), and (6) NAFL (imaging and spectroscopy endpoints of liver fat and biomarkers of hepatocellular injury [transaminases]). The last proposed analysis investigating the effect of small, "catalytic" doses of fructose will focus on all 6 outcomes.

Data synthesis. Meta-analyses will be conducted using the Generic Inverse Variance method applying random effects models expressed as standardized mean differences (SMDs) with 95% CIs. Paired analyses will be applied for crossover trials according to Elbourne et al. (Int J Epidemiol. 2002;31:140-149). Heterogeneity will be assessed by the Q statistic and quantified by I2. A priori subgroup analyses will be undertaken to explore sources of heterogeneity including the effect of underlying disease status, reference carbohydrate (comparator), fructose form, dose, follow-up, study design, baseline measurements, and study quality on the effect of fructose. Significant unexplained heterogeneity will be investigated by additional post hoc subgroup analyses (e.g. age, sex, level of feeding control, energy balance and composition of the background diet, etc.) and sensitivity analyses. Meta-regression analyses will assess the significance of subgroups analyses with piece-wise meta-regression techniques used to identify dose or follow-up thresholds. Publication bias will be investigated by inspection of funnel plots.

Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.

Preliminary findings: A pilot project which explored the effect of fructose on lipids in diabetes identified 786 articles, of which 14 (16 trials)were included in a meta-analysis. Isocaloric exchange of fructose for carbohydrate had a triglyceride raising effect in type 2 diabetes only where the reference carbohydrate was starch, dose was >60-g/d, or follow-up was ≤4-weeks. These distinctions had not been appreciated previously (Sievenpiper et al. Diabetes Care 2009;32:1930-1937).

Significance: The proposed project will aid in knowledge translation related to the effects of dietary fructose on diabetes, and cardiovascular risk factors, strengthening the evidence-base for recommendations and improving health outcomes through informing consumers and guiding future research.

Study Type Observational
Study Design Not Provided
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Varied.
Condition
  • Dyslipidemia
  • Diabetes
  • Prediabetes
  • Dysglycemia
  • Overweight
  • Obesity
  • Gout
  • Hypertension
  • Non-alcoholic Fatty Liver Disease
  • Metabolic Syndrome
  • Cardiovascular Disease
Intervention Other: Dietary fructose
Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: April 20, 2012)
1
Original Actual Enrollment
 (submitted: June 1, 2011)
0
Estimated Study Completion Date March 2016
Actual Primary Completion Date March 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Trials in humans
  • Oral fructose intervention
  • Suitable control (i.e. another carbohydrate source in isocaloric exchange for fructose or a control diet which is compared with the same diet supplemented with excess energy from fructose)
  • >= 7-days diet duration
  • Viable endpoint data

Exclusion Criteria:

  • Non-human studies
  • IV or parenteral fructose
  • High fructose corn syrup or sucrose intervention (except where these are the comparators)
  • Lack of a suitable control
  • < 7-days diet duration.
  • No viable endpoint data
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT01363791
Other Study ID Numbers CIHR-KS-2009-205030
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party John Sievenpiper, University of Toronto
Study Sponsor John Sievenpiper
Collaborators
  • Canadian Institutes of Health Research (CIHR)
  • Canada Research Chairs Endowment of the Federal Government of Canada
  • Calorie Control Council
Investigators
Study Director: John L Sievenpiper, MD, PhD Department of Pathology and Molecular Medicine, McMaster University and Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital
Principal Investigator: David JA Jenkins, MD, PhD, DSc Department of Nutritional Sciences and Medicine, University of Toronto and Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital
PRS Account University of Toronto
Verification Date May 2015